記念セッション
日本脳循環代謝学会50周年・60回記念セッション
司会：阿部 康二 （日本脳循環代謝学会 理事長） 峰松 一夫 （第60回日本脳循環代謝学会学術集会 会長）【式次第】
（1）開会の辞 阿部 康二 （日本脳循環代謝学会 理事長） （2）祝 辞 鈴木 則宏 （日本脳循環代謝学会 元理事長） （3）祝 辞 吉峰 俊樹 （日本脳循環代謝学会 前理事長） （4）祝 辞 Shinn-Zong Lin （国際脳循環代謝学会総会2001 会長） （5）祝 辞 Eng H. Lo （国際脳循環代謝学会 理事長） （6）祝 辞 菅野 巌 （国際脳循環代謝学会 元理事長） （7）祝 辞 木内 博之 （国際脳循環代謝学会総会2019 会長 国際脳循環代謝学会 次期理事長） （8）歴史紹介 阿部 康二 （日本脳循環代謝学会 理事長） （9）閉会の辞 阿部 康二 （日本脳循環代謝学会 理事長）招請講演 Ⅰ
CURRICULUM VITAE
Wolf-Dieter Heiss
Wolf-Dieter Heiss, born 31.12.1939 in Zell am See, Austria, graduated in medicine from the University of Vienna, Austria, in 1965. He achieved his training in neurology,
neurophysiology, psychiatry and nuclear medicine at the University hospital in Vienna and spent research fellowships at the MIT, Cambridge, USA, the Physiological Insti-tute in Stockholm, Sweden, the Department of Physiology of SUNY, Buffalo, NY and the Department of Neurology of the University of Minnesota, Minneapolis, USA. 1976 he was appointed associate professor at the Department of Neurology of the Universi-ty of Vienna. In 1978 he became director of the Center for Cerebrovascular Research of the Max Planck Institute for Brain Research and of the Department of Neurology of the City Hospital Cologne-Merheim, Germany. 1981 he was appointed as director at the Max Planck Institute for Neurological Research. 1985 – 2005 he was professor of neurology and chairman of the Department of Neurology of the University of Cologne and director of the Department of General Neurology at the MPI in Cologne. He was president of the International Stroke Society 1992-96, was on the board of directors of the Society for Cerebral Blood Flow and Metabolism, deputy editor of the Journal of Cerebral Blood Flow and Metabolism and at present is associate editor of the Journal of Nuclear Medicine and section editor of Stroke. He was chairman of the program committee of the European Federation of Neurological Societies (EFNS) 1998 - 2001 and was president of the EFNS 2001 – 2005. Since 2005 he is Visiting Professor at the Danube University in Krems, Austria, and since 2009 Adjunct Professor at the McGill University in Montreal, Canada and since 2013 Associate Professor at the University of Cluj, Romania, where he received a Doctor Honoris Causa in December 2014.
Multimodal brain imaging:
The role of PET in the past and prospects
for hybrid MR/PET in the future
Max Planck Institute for Metabolism Reserch， Cologne， Germany Wolf-Dieter Heiss Positron emission tomography (PET) imaging in clinical neurology serves several purposes: differential diagnosis, especially in the early stage of neurologic disorders, description of pathophysiologic changes that are responsible for manifestation and course of a disease, and evaluation and follow-up of treatment effects. Many of these applications are possible with the most widely available PET tracer, 2-deoxy-2-[18F] fluoro-D-glucose (FDG). Additional tracers are used clinically to detect the disturbance of specific neurotransmitter and receptor systems, blood flow, oxygen metabolism, and amino acid uptake. PET played a mayor role in early diagnosis of Alzheimer's disease and other dementias, differential diagnosis of movement disorders, diagnosis of recur-rent brain tumors, identification of viable tissue in ischemic stroke, and localization of epileptogenic foci. PET was also used for localization of brain areas involved in differ-ent tasks and for monitoring of therapeutic effects.
Multimodal imaging of physiologic and metabolic variables by PET requires coregistration to CT or MRI for accurate correspondence to the anatomic structures and to pathologic changes. MRI is the best method to image the morphology of the brain in health and disease, and various MR modalities can additionally be used to assess physiologic and metabolic parameters. Pooling information obtained with MRI and PET has long been performed through a parallel analysis of the sequentially acquired data and, more commonly today, by using software coregistration techniques. However, underlying such studies is the assumption that no significant changes in physiologic or cognitive conditions have occurred between the 2 examinations or after therapeutic intervention. One means to address such potential pitfalls is through the simultaneous collection of MRI and PET data. Fully integrated hybrid MR/PET scanners are now available for human whole-body imaging.
Simultaneous imaging improves coregistration and localization of anatomical structures
and lesions: This is of great advantage in the presurgical diagnosis of patients with focal epilepsy, in the management of brain tumors, for early recognition and differential diagnosis of cognitive impairment and for understanding the pathophysiology - e.g. deposition of amyloid, tau or other abnormal proteins - of degenerative disorders. Synergistic measurement of different physiologic parameters can explain functional impairment and predicts the development of irreversible neuronal damage in ischemic stroke and therefore is crucial for therapeutic decisions. Activation studies by PET and fMRI combined to diffusion tensor imaging permit the plotting of functional networks in health and disease and to demonstrate the effect of brain stimulation. Tracers for transmitters, receptors and encymes further elucidate the involvement of synaptic function in special tasks and uncover changes by diseases and drugs.
Utilizing the unique capacities of hybrid MR/PET for simultaneous real-time recording of functional, metabolic, physiologic and morphologic data opens innovative strategies to improve our insight into the complex function of the brain and to deepen our understanding of the pathophysiology of CNS disorders. MR/PET will play a crucial role in the transfer of developing therapeutic concepts from animal experiments to human application.
招請講演 Ⅱ
CURRICULUM VITAE
Eng H. Lo
Eng H. Lo received a BS in engineering at Yale, a PhD in biophysics from Berkeley, and completed a neuroscience fellowship at Stanford. Dr. Lo joined the Massachusetts General Hospital in 1991. His research interests include neuroprotection and neuroplas- ticity in stroke, brain injury and neurodegeneration, and in vivo imaging of brain func-tion.Help-me signaling in brain injury and repair
Massachusetts General Hospital， Boston， USA Eng H. Lo The concept of the neurovascular unit emphasizes that cell-cell signaling between neu-ral, glial and vascular compartments underlies mechanisms of both injury and repair in the CNS. In this seminar, we will survey examples of these biphasic pathways in cell, animal and translational model systems.
基調講演
北川 一夫（きたがわ かずお）
現 職 東京女子医科大学医学部 神経内科学 教授・講座主任 経 歴 昭和58年 3月 大阪大学医学部医学科卒業 昭和61年 7月 大阪大学医学部研究生（内科学第一教室） 平成 2年11月 米国コロンビア大学医学部研究員 平成 5年12月 医員（大阪大学医学部附属病院）（第一内科） 平成 9年10月 大阪大学助手（内科学第一教室） 平成19年 4月 大阪大学大学院医学系研究科准教授（神経内科学） 平成26年 4月 東京女子医科大学医学部 神経内科学 教授・講座主任 受 賞 平成 3年 日本脳卒中学会草野賞（脳虚血耐性現象の発見） 平成 8年 日本心臓財団研究奨励賞（脳卒中部門） 所属学会（役職） 日本脳卒中学会（ 理事、日米合同機関誌Journal of Stroke and Cerebrovascular Disease 編集委員長、2019年日本脳卒中学会学術集会会長予定） 日本神経学会（代議員、将来構想委員会委員、専門医認定委員会委員） 日本脳神経超音波学会（理事） 日本脳循環代謝学会（理事、機関誌脳循環代謝編集委員長2012-2016） 日本栓子検出と治療学会（理事、2017年日本栓子検出と治療学会会長） 日本神経治療学会（評議員） 日本脳ドッグ学会（評議員） 日本脳血管・認知症学会（理事）特別講演
Shinn-Zong (John) Lin M.D., Ph.D
Professor Lin focuses in Neuroscience, Stem Cell Thera-pies, Translational Science, and New Drug Development. President at Bioinnovation Center Buddhist Tzu Chi Med-ical Foundation. Dr. Lin is the Superintendent at Tzu Chi Hospital, Professor of Neurosurgery at Tzu Chi University, Taiwan. Dr. Lin got his M.D. from the National Defense Medical Center in 1980, and had been trained as Neurosurgical resident at Tri-Service General Hospital, Taipei, Taiwan during 1980-1986. He completed his Ph.D., program at Dept. Physiology and Biophysics and Dept. Neurological Surgery at State Universi-ty of New York at Stony Brook, U.S.A. from 1986-1989. He had ever been the President of Taiwan Neurosurgical Society; President of Asia Pacific Society of Neuroregeneration; President of International College of Surgeons, Taiwan section, Executive President of Asian Congress of Neurorestoratology and Congress President of 2001 International Society of Cerebral Blood Flow and Metab- olism. Moreover, he is the Chairman of Taiwan National Medical Licensing Examina-tion R.O.C. Dr. Lin is named as Fellow of American Association for the Advancement of Science (AAAS), International Fellow of American Association of Neurological Sur-gery (AANS) and Charter Fellow of National Academy of Inventors (NAI) USA. Dr. Lin serves on the 2017 NAI Fellows Advisory Committee (NAIFAC). Dr. Lin has published more than 120 papers in peer-reviewed since year 2012, and PUBMED cited Scientific journals. He is the editors of 27 books, and is the editorial board member of many scientific journals, including Hindawi Publishing Corporation, Stem Cells International, Journal of Neurology, Neurosurgery and Spine, Austin Jour- nal of Clinical Neurology; SciTz Neurosurgery and Spine, and Translational Neurosci-ence and Clinics. In addition, he is also the Coeditor-in-chief for Cell Transplantation (The Regenerative Medicine Journal science 2012 till now). He had conducted 9 clini-cal phase I/IIa trials. He has highly innovative 11 Technology Transfers; He owns 58 international Patents covering new drug development, in Angelicae Sinensis Extracts for treatment of Cancer, Pharmaceutical Compounds for treatment of Brain Cancer of Temozolomide Resistance of Brain Cancer Cells, and Methods for inhibiting autophagy of motor neurons, and stenosis of blood vessel as well as medical devices for stem cell navigation in the brain. Dr. Lin has been invited to give 288 lectures all over Asia, U.S.A, and Europe. − 48 −
基調講演
